Drug Discovery World
APRIL 18, 2023
billion by 2026, these drugs are primarily indicated for the treatment of multiple myeloma. AVA3996 is in pre-clinical development with the aim of submitting an Investigational New Drug (IND) application to allow clinical development to begin during 2024.
Drug Discovery World
MAY 23, 2024
AltruBio has closed an oversubscribed Series B financing of up to $225 million, which will be used to advance the clinical development of the first-in-class, novel immune checkpoint enhancer (ICE) PSGL-1 agonist antibody, ALTB-268. This study is anticipated to read out in 2H of 2026.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
NOVEMBER 23, 2023
This will push the Phase III CALYX trial forward and bring leriglitazone to patients as quickly as possible,” said Sílvia Pascual, VP Clinical Development, Minoryx. “In In patients with cALD, appearance of gadolinium-enhancing lesions typically precedes a phase with pronounced lesion growth and rapid clinical deterioration.
LifeSciVC
APRIL 2, 2024
We have milestones on the horizon, and we want investors to stay close to the Sionna story even if we don’t need capital until 2026. The insights from these internal discussions refined our messaging and helped demonstrate the compelling opportunity we have to advance a truly groundbreaking clinical development program.
The Pharma Data
OCTOBER 31, 2020
With the IND approval in place, we are ready and eager to extend the clinical study of TG-1000 to the U.S. billion USD by 2026 at a CAGR of 11.5%. Currently the market is comprised primarily of the neuraminidase inhibitor oseltamivir and the newly developed endonuclease inhibitor baloxavir. in the near future.”
The Pharma Data
JULY 6, 2021
Adjusted operating margins are expected to improve from the current mid-20s level to over 30% by 2026. The £33 billion sales ambition is before any significant revenue contribution from early-stage pipeline assets or any contribution from business development. Cash generated from operations is expected to exceed £10 billion by 2026.
The Pharma Data
JUNE 2, 2022
A 30-plus valent pneumococcal candidate vaccine is also in pre-clinical development. billion to be paid upon the achievement of certain paediatric clinical development milestones. The consideration for the acquisition comprises an upfront payment of $2.1 The transaction is expected to close in the third quarter of 2022.
Expert insights. Personalized for you.
242 
Let's personalize your content